# Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

> **NCT03187288** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 13 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Relapsed Cancer
- Refractory Cancer

## Interventions

- **DRUG:** CFI-400945 Fumarate

## Key facts

- **NCT ID:** NCT03187288
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-25
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03187288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03187288, "Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03187288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*